Welcome to Peptide Card of AntiTbPdb

This page displays user query in tabular form.

ACYCRIPACIAGERRYGTCIYQGRLWAFCC details

Primary information
ID	antitb_1132,
Name	11328767
N-Terminal modification	Human neutrophil defensin (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Internal disulphide bond (cys2-cys30, cys4-cys19,cys9-cys29)
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Protein Derived
Strain	From the human defensin protein found in granules of neutrophils.
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv (ATCC 25618)
Cell Line	50 mg/L causes approx 70 % growth inhibition
Inhibition Concentration	In vitro
Sequence	2001
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	Disrupt the membrane architecture
Other activities	Cell envelope
PMID	None
Year of Publication	Antibacterial against salmonella, staphylococcus and neisseria
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1133,
Name	11328767
N-Terminal modification	Human neutrophil defensin (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Internal disulphide bond (cys2-cys30, cys4-cys19,cys9-cys29)
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Protein Derived
Strain	From the human defensin protein found in granules of neutrophils.
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis E1380/94 MDR (Isoniazid, rifampicin, streptomycin, ethambutol) strain
Cell Line	50 mg/L causes approx 30 % growth inhibition
Inhibition Concentration	In vitro
Sequence	2001
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	Disrupt the membrane architecture
Other activities	Cell envelope
PMID	None
Year of Publication	Antibacterial against salmonella, staphylococcus and neisseria
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1223,
Name	23827033
N-Terminal modification	Human neutrophil peptide 1 (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulfide bridge: 2-30, 4-19, 9-29
Chirality	Cyclic
Nature	30
Source	L
Species	Protein Derived
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv
Cell Line	96.5 % inhibition at 10 Î¼g/ml
Inhibition Concentration	In vitro
Sequence	2013
Cytotoxicity	THP-1 cells
In vivo Model	Significant reduction in CFU
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	None
Year of Publication	None
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1224,
Name	23827033
N-Terminal modification	Human neutrophil peptide 1 (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulfide bridge: 2-30, 4-19, 9-30
Chirality	Cyclic
Nature	30
Source	L
Species	Protein Derived
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv
Cell Line	98.3 % inhibition at 15 Î¼g/ml
Inhibition Concentration	In vitro
Sequence	2013
Cytotoxicity	THP-1 cells
In vivo Model	Significant reduction in CFU
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	None
Year of Publication	None
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1225,
Name	23827033
N-Terminal modification	Human neutrophil peptide 1 (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulfide bridge: 2-30, 4-19, 9-31
Chirality	Cyclic
Nature	30
Source	L
Species	Protein Derived
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	36 Clinical isolates of Mycobacterium tuberculosis
Cell Line	11 isolates (31%) showed greater sensitivity to HNP-1 than H37Rv strains. At 15 Î¼g/ml, they wer completely inhibited.
Inhibition Concentration	In vitro
Sequence	2013
Cytotoxicity	THP-1 cells
In vivo Model	Sixteen clinical isolates had lower intracellular growth ability than the H37Rv strain.
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	None
Year of Publication	None
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1226,
Name	23827033
N-Terminal modification	Human neutrophil peptide 1 (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulfide bridge: 2-30, 4-19, 9-32
Chirality	Cyclic
Nature	30
Source	L
Species	Protein Derived
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium bovis
In Vitro/ In vivo	Mycobacterium bovis BCG
Cell Line	99.6 % inhibition at 10 Î¼g/ml
Inhibition Concentration	In vitro
Sequence	2013
Cytotoxicity	THP-1 cells
In vivo Model	Significant reduction in CFU
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	None
Year of Publication	None
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1227,
Name	23827033
N-Terminal modification	Human neutrophil peptide 1 (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulfide bridge: 2-30, 4-19, 9-33
Chirality	Cyclic
Nature	30
Source	L
Species	Protein Derived
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium bovis
In Vitro/ In vivo	Mycobacterium bovis BCG
Cell Line	100 % inhibition at 10 Î¼g/ml
Inhibition Concentration	In vitro
Sequence	2013
Cytotoxicity	THP-1 cells
In vivo Model	Significant reduction in CFU
Lethal Dose	NA
Immune Responce	None
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	None
Year of Publication	None
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1370,
Name	11375668
N-Terminal modification	Human neutrophil peptides-1
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29
Chirality	cyclic
Nature	30
Source	L
Origin	Cationic
Species	Synthetic
Strain	Human neutrophils
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37 Ra
Inhibition Concentration	in vitro
Sequence	2000
Cytotoxicity	None
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	Mycobacterial genomic DNA
PMID	NA
Year of Publication	antibacterial against candida albicans
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1527,
Name	25681127
N-Terminal modification	Human neutrohil peptide (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29
Chirality	cyclic
Nature	30
Source	L
Origin	Cationic
Species	Synthetic
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv
Inhibition Concentration	in vitro
Sequence	2015
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target
Combination Therapy	Inteacting with microbial membrane
Other activities	NA
PMID	NA
Year of Publication	Antibacterial against E.coli, S.aureus, bacillus, pseudomonas
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1651,
Name	10933095
N-Terminal modification	Human neutrohil peptide (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Synthetic
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium Tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv
Cell Line	IC50 = 0.8Î¼g/ml
Inhibition Concentration	in vitro
Sequence	2016
Cytotoxicity	murine macrophage-like cell line J744A.1
In vivo Model	NA
Lethal Dose	cytotoxic at above concentration 5 ug/ml
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	Microbial membrane disruption
Other activities	NA
PMID	NA
Year of Publication	NA
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1652,
Name	10933095
N-Terminal modification	Human neutrohil peptide (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Synthetic
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium Tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis H37Rv
Cell Line	IC90 = 2.5 Î¼g/ml
Inhibition Concentration	in vitro
Sequence	2016
Cytotoxicity	murine macrophage-like cell line J744A.1
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	Microbial membrane disruption
Other activities	NA
PMID	NA
Year of Publication	NA
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1702,
Name	8641802
N-Terminal modification	Human neutrophil peptide (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Natural
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis Ra 7632G
Cell Line	Reduction in CFU at 50 Î¼g/ml
Inhibition Concentration	in vitro
Sequence	1996
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	Microbial membrane disruption
Other activities	NA
PMID	NA
Year of Publication	NA
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1703,
Name	8641802
N-Terminal modification	Human neutrophil peptide (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys30
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Natural
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis Ra 9034G
Cell Line	Reduction in CFU at 50 Î¼g/ml
Inhibition Concentration	in vitro
Sequence	1996
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	Microbial membrane disruption
Other activities	NA
PMID	NA
Year of Publication	NA
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1704,
Name	8641802
N-Terminal modification	Human neutrophil peptide (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys31
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Natural
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium tuberculosis
In Vitro/ In vivo	Mycobacterium tuberculosis Ra 11170G
Cell Line	Reduction in CFU at 50 Î¼g/ml
Inhibition Concentration	in vitro
Sequence	1996
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	Microbial membrane disruption
Other activities	NA
PMID	NA
Year of Publication	NA
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1716,
Name	1398982
N-Terminal modification	Human neutrophil peptide (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Natural
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium avium- mycobacterium intracellularae
In Vitro/ In vivo	Mycobacterium avium- mycobacterium intracellularae strain 25291
Cell Line	Reduction in CFU at 5 Î¼g/ml
Inhibition Concentration	in vitro
Sequence	1992
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	NA
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1717,
Name	1398982
N-Terminal modification	Human neutrophil peptide (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Natural
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium avium- mycobacterium intracellularae
In Vitro/ In vivo	Mycobacterium avium- mycobacterium intracellularae strain 25291
Cell Line	Reduction in CFU at 50 Î¼g/ml
Inhibition Concentration	in vitro
Sequence	1992
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	NA
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1718,
Name	1398982
N-Terminal modification	Human neutrophil peptide (HNP-2)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys1-cys29, cys3-cys18,cys8-cys28
Chirality
Nature	29
Source	L
Origin	Cationic
Species	Natural
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium avium- mycobacterium intracellularae
In Vitro/ In vivo	Mycobacterium avium- mycobacterium intracellularae strain 25291
Cell Line	Reduction in bacterial load to 64 % at 5 Î¼g/ml
Inhibition Concentration	in vitro
Sequence	1992
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	NA
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1720,
Name	1398982
N-Terminal modification	Human neutrophil peptide (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Natural
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium avium- mycobacterium intracellularae
In Vitro/ In vivo	Mycobacterium avium- mycobacterium intracellularae strain SJB
Cell Line	Reduction in CFU/well 91.8 Â± 1.1 at peptide concentration 50Î¼g/ml
Inhibition Concentration	in vitro
Sequence	1992
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	NA
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1721,
Name	1398982
N-Terminal modification	Human neutrophil peptide (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Natural
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium avium- mycobacterium intracellularae
In Vitro/ In vivo	Mycobacterium avium- mycobacterium intracellularae strain 292524
Cell Line	Reduction in CFU/well70.6 Â± 0.6 at peptide concentration 50Î¼g/ml
Inhibition Concentration	in vitro
Sequence	1992
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	NA
Tertiary Structure (Technique)	Not Predicted),

Primary information
ID	antitb_1722,
Name	1398982
N-Terminal modification	Human neutrophil peptide (HNP-1)
C-Terminal Modification	ACYCRIPACIAGERRYGTCIYQGRLWAFCC
Chemical Modification	Free
Linear/Cyclic	Free
Length	Disulphide linkage between cys2-cys30, cys4-cys19,cys9-cys29
Chirality	Cyclic
Nature	30
Source	L
Origin	Cationic
Species	Natural
Strain	Human neutrophil
Inhibition Concentration	Mycobacterium avium- mycobacterium intracellularae
In Vitro/ In vivo	Mycobacterium avium- mycobacterium intracellularae strain 475049
Cell Line	Reduction in CFU/well 32.5 Â± 10.7 at peptide concentration 50Î¼g/ml
Inhibition Concentration	in vitro
Sequence	1992
Cytotoxicity	NA
In vivo Model	NA
Lethal Dose	NA
Immune Responce	NA
Mechanism of Action	NA
Target	NA
Combination Therapy	NA
Other activities	NA
PMID	NA
Year of Publication	NA
Tertiary Structure (Technique)	Not Predicted),